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ABSTRACT 
Objective: The main objective of this work was to design, synthesize and evaluate the novel pyrazoline incorporated 1,2,3-triazole benzene 
sulphonamides for cytotoxic and anti-gout activities also to perform Insilco molecular docking studies. 
Methods: Designed compounds were synthesized by condensation of different substituted chalcones (3a-i) with hydrazine hydrate and substituted 
phenylhydrazines. All the synthesized compounds were characterized on the basis of physical and spectral data. To predict the affinity and activity 
of the ligand molecule Libdock program was employed to generate different bioactive binding poses of designing molecules at the active site of 
protein Phosphatidylinositol 3-kinase (PI3Kα). Title compounds were evaluated for cytotoxic activity by using 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and anti-gout activity by potassium oxonate induced assay. 
Results: All the synthesized compounds showed characteristic peaks in FTIR, 1H, 13C NMR and MASS spectral analysis. In molecular docking studies, 
compound 3i has shown good binding affinity to the active site of PI3Kα with a docking score of 145.031 and 4 hydrogen bonding interactions with 
least hepatotoxicity and good bioavailability when compared with that of reference ligand KKR exhibited a Libdock score of 88.35. Remaining 
compounds also have a good binding affinity with a minimum of 2 bonding interactions and having better absorption, distribution, metabolism, 
elimination and toxicity (ADMET) profile. The same compound (3i) exhibited the highest cytotoxic activity with an IC50 value of 4.54µg/ml. 
Compound 4d was evaluated for anti-inflammatory activity and it has significantly ameliorated against potassium oxonate induced gout in mice 
when compared with that of standard drug allopurinol due to its anti-inflammatory property. 
Conclusion: We designed and synthesized a novel series of title compounds in quantitative yields and performed docking studies. New derivatives 
have a good binding affinity towards PI3Kα enzyme, good bioavailability, least hepatotoxicity and significant cytotoxic activity. 
Keywords: ADMET, Cancer, Docking, Malignant, PI3Kα, Proliferation 




Cancer is a multifactorial disease, arising from the uncontrolled 
proliferation of a cell with the potential to invade to other organs of 
the body [1]. PI3Kα is one of the proto-oncogenes, which has a vital 
role in the regulation of many important cell signaling pathways 
including cellular replication, cell proliferation leading to growth 
and apoptosis [2, 3]. The enzyme PI3Kα appeared to involve in 40% 
of all types of human cancers including breast, gastric, cervical, 
urinary tract, colon, non-small-cell lung and squamous cell lung 
carcinomas [4]. Considerable evidence suggest that PI3K (P110α) 
subunit protein is expected to mutate in these cancers that bring 
about constitutive downstream pathways leading to defective 
control of cellular proliferation and malignant transformation, thus 
PI3Kα is drawing attention in cancer biology [5,6]. Hence targeting 
PI3Kα may be considered as a promising approach in the design of 
new anticancer drugs. 
Pyrazoles are a class of heterocyclic compounds characterized by 5-
membered aromatic ring structure composed of three carbon atoms 
and two nitrogen atoms in adjacent positions. Pyrazole derivatives 
have a long history of applications in agriculture as herbicides and 
insecticides as well as in the pharmaceutical industry as antipyretic 
and anti-inflammatory agents [7-12]. Pyrazole derivatives have been 
reported to show a broad spectrum of biological activity including 
antibacterial [13], antifungal [14], analgesic [15], anti-inflammatory 
[16-18], neuroprotective [19], estrogen receptor binding [20], 
antineoplastic [21], activities. Due to their wide range of biological 
activities, pyrazoles received considerable interest in the field of 
drug discovery and therefore pyrazole ring constitutes a relevant 
synthetic target in the pharmaceutical industry. On the other hand, 
1,2,3-triazole is an important heterocycle which has gained a lot of 
interest for researchers in view of its high potency, low toxicity with 
broad spectrum of activities. Triazole derivatives have been 
reported to have anticancer [22], anti-inflammatory [23], 
antibacterial [24], antiviral [25], anti-human immuno virus (HIV) 
[26], fungicidal [27] and insecticidal [28-30] activities. The objective 
of the current work was to synthesize novel pyrazoline 
incorporating 1,2,3-triazole benzene sulphonamide derivatives as 
potent antiproliferative and anti-inflammatory agents. We were well 
known about the synthesis of simple pyrazolines from chalcones but 
we designed pyrazoline incorporating 1,2,3-triazolyl benzene 
sulphonamide derivatives. Inspired by the biological properties of 
both pyrazole and triazole heterocycles in the present study, we 
thought of synchronizing both these moieties into a single molecule 
in order to obtain new hybrid molecules with improved biological 
activity and low toxicity.  
MATERIALS AND METHODS 
All the chemicals and solvents used were of synthetic grade from SD 
fine chemicals Ltd., (Mumbai, India), and avra chemicals pvt ltd 
Hyderabad. Completion of the reaction was monitored by analytical 
thin layer chromatography (TLC) using E-Merck 0.25 mm silica gel 
plates. Visualization was accomplished with ultraviolet (UV) light 
(256 nm) and iodine chamber. Synthesized compounds were 
purified by the re-crystallization process. The purity of the 
compounds was checked by a single spot in TLC and solvent system 
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for TLC was determined on trial and error basis. Melting points were 
determined in open capillary tubes using ANALAB melting point 
apparatus and were uncorrected. All the 1H NMR spectra were 
recorded on varian 400 MHz spectrometer using DMSO-d6 as solvent 
and tetramethylsilane (TMS) as an internal standard. Chemical shift 
values are listed in δ scale. The FT-IR spectra were recorded on 
schimadzu FT-IR spectrophotometer by using 1% potassium 
bromide discs. Mass spectra of the compounds were recorded on 
electronic spin ionization mass spectra (ESI-MS) on aglient 1100 
series. 
Synthesis of 4-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-yl) benzene 
sulfonamide (2) 
Sodium metal was dissolved in 10 ml of absolute ethanol in a dry 
flask to which azido benzene sulfonamide and 2 ml of acetylacetone 
were added and stirred for 1 h on magnetic stirrer. Transferred to 
the round-bottomed flask (RBF) and refluxed at 140 °C for 12-16 h. 
The completion of the reaction was monitored by TLC. The reaction 
mixture was poured into crushed ice to obtain the solid product. 
Then the precipitate was filtered under suction, washed thoroughly 
with water and recrystallized from aq. methanol.  
Synthesis of substituted 4-(4-(3-(phenyl)acryloyl)-5-methyl-
1H-1,2,3-triazol-1-yl)benzenesulfonamide derivatives 3(a-i) 
Different substituted benzaldehydes (0.01 mol) and 4-(4-acetyl-5-
methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide 2 (0.01 mol) were 
dissolved in 95% of ethanol in a conical flask to this added NaOH 
pellet the reaction mixture was stirred for 30 min. The solid 
obtained was collected and recrystallized from absolute ethanol.  
Synthesis of substituted 4-(4-(5-(phenyl)-4,5-dihydro-1H-pyrazol-
3-yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide 
derivatives 4(a-l) 
Substituted chalcones 3(a-o) (0.01 mol), hydrazine hydrate (0.015 
mol) were mixed in ethanol in a RBF and refluxed for 3 h. The 
completion of the reaction was monitored by TLC. The reaction 
mixture was poured into crushed ice to obtain the solid product. 
Solid was collected and recrystallized from methanol.  
Synthesis of substituted 4-(5-methyl-4-(5-phenyl-4,5-dihydro-
1H-pyrazol-3-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide 
5(a-i) 
Substituted chalcones 3(a-o) (0.01 mol), substituted phenyl 
hydrazines (0.01 mol) and a catalytic amount of glacial acetic acid 
were refluxed in ethanol in RBF for 4-5 h After completion of the 
reaction, the reaction mixture was poured into crushed ice to obtain 
the solid product. Then solid was collected and recrystallized from 
aq. ethanol. 
Molecular docking and ADMET studies 
The molecular docking study of synthesized compounds was done 
by employing the Libdock protocol in order to identify binding 
interactions with the target protein PI3Kα (PDB ID: 3ZIM). ADMET 
studies were carried out by using discovery studio software. 
Cytotoxic activity 
The title compounds were evaluated for In vitro antiproliferative 
activity via MTT ([3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide]) based cytotoxic assay[31] against MCF-7 
breast cancer cell line with taxol as standard reference. Cell lines 
were purchased from the national institute of nutrition (NIN) 
Hyderabad. Cells were harvested from the logarithmic phase of 
cultures and re-suspended in Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% fetal bovine serum (FBS). The cell counts 
were adjusted and equal number of cells were plated into each well 
of 96-well culture plates and allowed to grow overnight at 37 °C, in 
presence of 5% CO2. The cells were treated with test substances at 
various concentrations as indicated for 72h. In vehicle control 
culture wells, a maximum of 0.5% DMSO was added. Culture 
medium was renewed at every 24h with fresh culture medium 
supplemented with test substances. Thereafter, 0.5 mg/ml of MTT 
reagent was added to each well and the microplate was incubated 
further for 4h at 37 °C in presence of 5% CO2. Finally, the cells were 
solubilized by adding solubilizing solution and allowed to incubate 
at 37 °C overnight. After complete solubilization of the formazan 
crystals the absorbance was read at 540 nm in a microplate reader 
(Bio-Rad, USA). The results (mean OD±SD) obtained from 
quadruplicate wells were used in the calculation to determine the 
cytotoxicity (50% of inhibitory concentration, IC50) of the test 
compounds.  
Evaluation of anti-inflammatory effect of compound 4d against 
potassium oxonate induced gout in mice 
Anti-inflammatory activity of compound 4d in potassium oxonate 
induced gout in mice was investigated in the present study. Intra-
peritoneal injections of potassium oxonate 250 mg/kg daily for 28 d 
has lead to increased levels of serum concentration of creatinine, 
uric acid, blood urea nitrogen, and xanthine oxidase enzyme level as 
an indicator of impaired kidney function and increased plasma 
concentration of the blood parameters such as total leukocyte count, 
differential leukocyte count and erythrocyte sedimentation rate 
(ESR) indicates inflammation. Treatment with compound 4d in 
doses 50 mg/kg and 100 mg/kg for 28 d exhibited a significant 
improvement in gout disease in mice as evidenced by the decrease 
in biochemical parameters and inflammation in joints. The total 
leukocyte count, differential leukocyte count and erythrocyte 
sedimentation rate were estimated as per reported methods. 
Creatinine level was determined in serum by using modified jaffe’s 
reaction. The level of xanthine oxidase was determined by. Uric acid 
level was determined in serum by using peroxidase endpoint assay. 
Blood urea nitrogen level was determined by using berthelot end 
point assay. Present study indicated that the group of mice given 
standard reference compound allopurinol at 5 mg/kg body weight 
significantly (p<0.05) reduced serum creatinine, uric acid, blood urea 
nitrogen, and xanthine oxidase enzyme level in hyperuricemic mice. 
Male albino mice were obtained from Sainath Agencies Hyderabad. 
They were acclimatized to laboratory conditions (22±2 ˚C of 
temperature, 12-hr light/dark cycle), food and water were given ad 
libitum. After an acclimatization period of 2 w, they were randomly 
divided into 5 experimental groups.  
To evaluate Anti-inflammatory effect of Quinoline-3-carbonitrile 
derivative against potassium oxonate induced gout in mice. 30 Male 
albino mice weighing 25-30 gm were randomly divided into five 
groups of six mice in each group such as:  
Group 1: Normal control (received saline p. o daily for 28 d). 
Group 2: Disease control (received potassium oxonate 250 mg/kg i. 
p for 28 d). 
Group 3: Standard control (received potassium oxonate 250 mg/kg 
i. p and allopurinol 5 mg/kg p. o for 28 d). 
Group 4: Low dose group (received potassium oxonate 250 mg/kg i. 
p and Quinoline-3-carbonitrile derivative 50 mg/kg p. o for 28 d). 
Group 5: High dose group (received potassium oxonate 250 mg/kg 
i. p and Quinoline-3-carbonitrile derivative 100 mg/kg p. o for 28 d). 
All the groups except normal control have received potassium 
oxonate 250 mg/kg intraperitoneally for 28 d and 1 hour later, 
standard group and treatment groups have received allopurinol (5 
mg/kg p. o) and quinoline-3-carbonitrile (low dose-50 mg/kg and 
high dose-100 mg/kg p. o) respectively. Differential leukocyte count 
and total leukocyte count were estimated on 7th, 14th and 29th day by 
collecting blood through retro-orbital plexus. On 29thday blood 
samples were collected for estimating biochemical parameters and 
later on all animals were sacrificed for histopathological studies.  
All the experimental procedures were carried out in accordance 
with the committee for the purpose of control and supervision of 
experiments on animals (320/CPCSCEA dated 03-01-2001) 
guidelines. The study was reviewed and approved by the 
Institutional Animal Ethics Committee (GPRCP/IAEC/ 10/18/ 
02/PCL/AE-2-Mice-M/F-30), G. Pulla Reddy College of Pharmacy, 
Mehdipatnam, Hyderabad, India. 
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RESULTS AND DISCUSSION 
Chemistry 
The synthesis of compounds 4(a-l) and 5(a-i) is given under fig 1. In 
this scheme, the intermediate 4-(4-acetyl-5-methyl-1H-1,2,3-triazol-1-
yl)benzenesulfonamide (2) was synthesized by diazotization of 4-
amino benzene sulphonamide and followed by condensation of 4-
azidobenzene sulphonamide with acetylacetone in presence of sodium 
ethoxide under reflux for 12-15 h. Claisen Schmidt condensation 
reaction of intermediate (2) with various substituted aromatic 
aldehydes under basic conditions gave chalcones 3(a-l). In the final 
step, reaction of chalcones 3(a-l) with hydrazine hydrate in ethanol 
under reflux for 3-4 h gave 4-(5-methyl-4-(5-phenyl-4,5-dihydro-1H-
pyrazol-3-yl)-1H-1,2,3-triazol-1-yl) benzene sulfonamides 4(a-l) (Step 
4A) in good yields. Simultaneously, intermediate (3) condensed with 
different substituted phenylhydrazines in ethanol under reflux for 4-
5 h to obtain 4-(5-methyl-4-(5-phenyl-4,5-dihydro-1H-pyrazol-3-
yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamides of series-2 [5(a-i)] 
(Step 4B) in good yields. All the derivatives were characterized by 1H 
NMR, IR and ESI-MASS spectral data.  
The 1H NMR spectrum of final compounds contains a singlet around 
2.61 ppm for CH3 protons, protons of CH2 and CH of pyrazoline ring 
appeared as doublet of doublets, triplet of doublets in the range of 3-
5 ppm, aromatic protons appeared in the range of 6.5-8.2 ppm and 
two protons of–NH2 appeared as a singlet at 7.6 ppm whereas one 




Fig. 1: Synthesis of pyrazoline incorporated 1,2,3-triazole benzene sulphonamide derivatives 
 
Spectral characterization of synthesized compounds 
4-(4-Acetyl-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide 
(2): Yield 95%, mp 129-131 °C. IR spectrum, ν, cm-1: 1174, 1357, 
1689, 3192, 3273. 1H NMR (400 MHz, DMSO-d6): 2.56 (s, 3H, CH3), 
2.65 (s, 3H, COCH3), 7.61 (s, 2H,-NH2), 7.88 (dd, 2H, ArH, J= 6.9 Hz), 
8.08 (dd, 2H, ArH, J=9.0Hz). ESI-MS: m/z 281 (M+1) observed for 
C11H12N4O3S. 
4-(4-Cinnamoyl-5-methyl-1H-1,2,3-triazol-1-yl)benzene 
sulfonamide (3a): Yield 95%, mp 340-342 °C. IR spectrum, ν, cm-1: 
1174, 1357, 1656, 3192, 3273. 1H NMR (400 MHz, DMSO-d6): 2.61 (s, 
3H,-CH3), 7.51 (t, 3H, ArH), 7.6 (s, 2H,-NH2), 7.75 (d, 2H, olefinic, 
ArH), 7.8-8.05 (m, 6H, ArH and NH2). ESI-MS: m/z 369 (M+1) 
observed for C18H16N4O3S. 
4-(4-(3-(4-Chlorophenyl)acryloyl)-5-methyl-1H-1,2,3-
triazol-1-yl)benzene sulfonamide (3b): Yield 97%, mp 360-
361 °C. IR spectrum, ν, cm-1: 1091, 1159, 1315, 1664, 3304, 
3350. 1H NMR (400 MHz, DMSO-d6): 2.61 (s, 3H, CH3), 7.5 (d, 2H, 
ArH, J= 6.9 Hz), 7.6 (d, 2H, ArH), 7.8-7.95 (m, 7H, ArH and NH2, 
olefinic), 8.02 (d, 1H, olefinic). ESI-MS: m/z 403 (M+1) observed 
for C18H15ClN4O3S. 
4-(4-(3-(4-Methoxyphenyl)acryloyl)-5-methyl-1H-1,2,3-
triazol-1-yl)benzene sulfonamide (3c): Yield 98%, mp 260-
262 °C. IR spectrum, ν, cm-1: 1031, 1164, 1345, 1654, 3213, 
3396. 1H NMR (400 MHz, DMSO-d6): 2.61 (s, 3H, CH3), 3.81 (s, 
3H, OCH3), 6.9-7.1 (m, 4H, olefinic and ArH), 7.78-7.9 (m, 6H, 
ArH, NH2), 8.0 (d, 2H, ArH, J= 7.0 Hz). ESI-MS: m/z 399 (M+1) 
observed for C19H18N4O4S. 
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4-(5-Methyl-4-(3-(thiophen-2-yl)acryloyl)-1H-1,2,3-triazol-1-
yl)benzene sulfonamide (3d): Yield 98%, mp 350-352 °C. IR 
spectrum, ν, cm-1: 1101, 1305, 1656, 3298, 3340. 1H NMR (400 MHz, 
DMSO-d6): 2.61 (s, 3H, CH3), 7.2 (d, 1H, olefinic), 7.57-7.65 (m, 4H, 
ArH), 7.71 (s, 2H, NH2), 7.8 (d, 1H, ArH), 7.9 (d, 2H, ArH), 8.02 (d, 1H, 
olefinic). ESI-MS: m/z 375 (M+1) observed for C16H14N4O3S2. 
4-(4-(3-(Furan-2-yl)acryloyl)-5-methyl-1H-1,2,3-triazol-1-yl) 
benzenesulfonamide (3e): Yield 95%, mp 210-212 °C. IR 
spectrum, ν, cm-1: 1163, 1344, 1654, 3255, 3334. 1H NMR (400 MHz, 
DMSO-d6): 2.61 (s, 3H, CH3), 7.2 (d, 1H, olefinic), 7.57-7.6 (m, 4H, 
ArH), 7.61 (s, 2H, NH2), 7.8 (d, 1H, ArH), 7.9 (d, 2H, ArH), 8.02 (d, 1H, 
olefinic). ESI-MS: m/z 359 (M+1) observed for C16H14N4O4S. 
4-(4-(3-(4-(Dimethylamino)phenyl)acryloyl)-5-methyl-1H-1,2,3-
triazol-1-yl) benzenesulfonamide (3f): Yield 90%, mp 252-254 °C. 
IR spectrum, ν, cm-1: 1134, 1357, 1653, 3253, 3334. 1H NMR (400 MHz, 
DMSO-d6): 2.61 (s, 3H, CH3), 2.95 (s, 6H, N(CH3)2), 7.41-7.44 (m, 3H, 
ArH and olefinic), 7.7-7.95 (m, 6H, ArH, NH2, olefinic), 7.96-8.15 (m, 
3H, ArH). ESI-MS: m/z 412 (M+1) observed for C20H21N5O3S. 
4-(5-Methyl-4-(5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-1H-
1,2,3-triazol-1-yl) benzene sulfonamide (4a): Yield 69%, mp 203-
205 °C. IR spectrum, ν, cm-1: 761, 1165, 1346, 1592, 2370, 3259, 
3352. 1H NMR (400 MHz, DMSO-d6):2.61 (s, 3H, CH3), 3.2 (dd, 1H, 
CH2), 4.1 (dd, 1H, CH2), 5.9 (td, 1H,-CH), 7.15-7.41 (m, 5H, ArH), 7.6 
(s, 2H, NH2), 7.7-7.95 (m, 3H, ArH, NH), 8.0-8.17 (m, 2H, ArH). [13]C 
NMR (100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 
124.5, 125.5, 127.9, 128.4, 128.8, 132.0, 132.3, 139.6, 142.3, 145.8(C-
Ar), 145.2 (C-SO2). ESI-MS: m/z 383 (M+1) observed for 
C18H17N6O2S, Anal calcd: C, 56.53; H, 4.74; N, 21.97; O, 8.37; S, 8.38, 
found: C, 55.53; H, 5.38; N, 20.38, O, 8.97; S, 9.74; 
4-(4-(5-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-methyl 
-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4b): Yield 78%, mp 
155-158 °C. IR spectrum, ν, cm-1: 836, 1161, 1306, 1593, 2372, 3259, 
3332. 1H NMR (400 MHz, DMSO-d6); 2.61 (s, 3H,-CH3), 2.9 (dd, 1H,-
CH2), 3.6 (dd, 1H,-CH2), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 7.6 (s, 2H,-
NH2), 7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, ArH). [13]C NMR 
(100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 125.9, 
127.5, 128.8, 128.9, 132.0, 132.3, 138.4, 139.6, 142.3, 143.8 (C-Ar), 
145.2 (C-SO2). ESI-MS: m/z 417 (M+1) observed for C18H17ClN6O2S, 
Anal calcd: C, 51.86; H, 4.11; Cl, 8.50; N, 20.16; O, 7.68; S, 7.69; found: C, 
52.11; H, 3.86; Cl, 8.60; N, 21.16; O, 7.68; S, 6.59; 
4-(4-(5-(2-Chlorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-
methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4c): Yield 76%, 
mp 158-160 °C. IR spectrum, ν, cm-1: 762, 1159, 1352, 1593, 2361, 
3258, 3352. 1H NMR (400 MHz, DMSO-d6): 2.61 (s, 3H,-CH3), 2.9 (dd, 
1H,-CH2), 3.6 (dd, 1H,-CH2), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 7.6 (s, 
2H,-NH2), 7.7 (s, 1H,-NH), 7.9-8.1 (m, 4H, ArH). [13]C NMR (100 MHz, 
DMSO-d6): δ 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 125.9, 127.5, 128.8, 
128.9, 132.0, 132.3, 138.4, 139.6, 142.3, 143.8 (C-Ar), 145.2 (C-SO2). 
ESI-MS: m/z 417 (M+1) observed for C18H17ClN6O2S, Anal calcd: C, 
51.86; H, 4.11; Cl, 8.50; N, 20.16; O, 7.68; S, 7.69; found: C, 52.11; H, 
3.86; Cl, 8.60; N, 21.16; O, 7.68; S, 6.59; 
4-(4-(5-(4-Fluorophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-methyl 
-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4d): Yield 95%, mp 
156-158 °C. IR spectrum, ν, cm-1: 839, 1167, 1305, 1594, 2361, 3265, 
3352. 1H NMR (400 MHz, DMSO-d6) 2.61 (s, 3H,-CH3), 2.9 (dd, 1H,-
CH2), 3.6 (dd, 1H,-CH2), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 7.6 (s, 2H,-
NH2), 7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, ArH). [13]C NMR 
(100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 119.5, 
127.5, 128.8, 128.9, 132.0, 132.3, 139.6, 142.3, 143.8 (C-Ar), 145.2 (C-
SO2). 147.5 (C-F). ESI-MS: m/z 401 (M+1) observed for C18H17FN6O2S, 
Anal calcd: C, 53.99; H, 4.28; F, 4.74; N, 20.99; O, 7.99; S, 8.01; found: C, 
52.28; H, 5.99; F, 5.00; N, 20.74; O, 8.99; S, 7.00; 
4-(4-(5-(4-Bromophenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-
methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4e): Yield 
72%, mp 165-167 °C. IR spectrum, ν, cm-1: 826, 1154, 1305, 1594, 
2361, 3265, 3352. 1H NMR (400 MHz, DMSO-d6) 2.61 (s, 3H,-CH3), 2.9 
(dd, 1H,-CH2), 3.6 (dd, 1H,-CH2), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 7.6 
(s, 2H,-NH2), 7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, ArH). [13]C 
NMR (100 MHz, DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 124.4, 
126.9, 127.5, 128.8, 128.9, 132.3, 138.4, 139.6, 142.3, 143.8 (C-Ar), 
145.2 (C-SO2). ESI-MS: m/z 461 (M+1) observed for C18H17BrN6O2S, 
Anal calcd: C, 46.86; H, 3.71; Br, 17.32; N, 18.22; O, 6.94; S, 6.95; found: 
C, 45.95; H, 4.71; Br, 17.22; N, 18.36; O, 6.94; S, 6.82; 
4-(4-(5-(4-Methoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-
methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4f): Yield 73 
%, mp 165-167 °C. IR spectrum, ν, cm-1: 1029, 1153, 1338, 1593, 
2362, 3259, 3324. 1H NMR (400 MHz, DMSO-d6) 2.59 (s, 3H, CH3), 2.9 
(dd, 1H, CH2), 3.58 (dd, 1H, CH2), 3.77 (s, 3H, OCH3), 4.8 (td, 1H, CH), 
6.9 (d, 2H, ArH), 7.3 (d, 2H, ArH), 7.55-7.65 (m, 3H, NH2, NH), 7.9 (d, 
2H, ArH), 8.13 (d, 2H, ArH). [13]C NMR (100 MHz, DMSO-d6) δ: 10.4 
(CH3), 42.3 (C-Py), 55.6 (OCH3), 62.2 (C-N), 123.9, 127.5, 128.8, 
128.9, 132.0, 132.3, 139.6, 142.3, 143.8 (C-Ar), 145.2 (C-SO2), 151.9 
(ArC-OCH3). ESI-MS: m/z 413 (M+1) observed for C19H20N6O3S, Anal 
calcd: C, 55.33; H, 4.89; N, 20.38; O, 11.64; S, 7.76; found: C, 56.33; H, 
3.77; N, 21.64; O, 10.38; S, 7.88; 
4-(5-Methyl-4-(5-(p-tolyl)-4,5-dihydro-1H-pyrazol-3-yl)-1H-
1,2,3-triazol-1-yl)benzenesulfonamide (4g): Yield 73 %, mp 210-
213 °C. IR spectrum, ν, cm-1: 1153, 1352, 1596, 2362, 3259, 3324. 1H 
NMR (400 MHz, DMSO-d6) 2.59 (s, 6H,2-CH3), 2.9 (dd, 1H, CH2), 3.48 
(dd, 1H, CH2), 4.77 (td, 1H, CH), 6.9 (d, 2H, ArH), 7.3 (d, 2H, ArH), 
7.55-7.65 (m, 3H, NH2, NH), 7.9 (d, 2H, ArH), 8.13 (d, 2H, ArH). [13]C 
NMR (100 MHz, DMSO-d6) δ: 10.4 (CH3), 21.2, 42.3 (C-Py), 62.2 (C-
N), 125.9, 127.5, 128.8, 128.9, 132.0, 132.3, 138.4, 139.6, 142.3, 
143.8 (C-Ar), 145.2 (C-SO2). ESI-MS: m/z 397 (M+1) observed for 
C19H20N6O2S, Anal calcd: C, 57.56; H, 5.08; N, 21.20; O, 8.07; S, 8.09; 
found: C, 56.08; H, 6.56; N, 20.09; O, 9.07; S, 8.20; 
4-(5-Methyl-4-(5-(4-nitrophenyl)-4,5-dihydro-1H-pyrazol-3-
yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4h): Yield 75 %, 
mp 205-207 °C. IR spectrum, ν, cm-1: 1174, 1357, 1595, 3262, 3373. 
1H NMR (400 MHz, DMSO-d6) 2.61 (s, 3H,-CH3), 2.9 (dd, 1H,-CH2), 3.6 
(dd, 1H,-CH2), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 7.6 (s, 2H,-NH2), 
7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, ArH). [13]C NMR (100 
MHz, DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 62.2 (C-N), 125.9, 127.5, 
128.8, 128.9, 132.0, 132.3, 139.6, 142.3, 143.8(C-Ar),, 145.2(C-SO2), 
149.2 (C-NO2). ESI-MS: m/z 428 (M+1) observed for C18H17N7O4S, 
Anal calcd: C, 50.58; H, 4.01; N, 22.94; O, 14.97; S, 7.50; found: C, 
50.50; H, 5.58; N, 22.01; O, 14.94; S, 6.97; 
4-(4-(5-(2,4-Dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-3-yl)-5-
methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4i): Yield 65 
%, mp 210-212 °C. IR spectrum, ν, cm-1: 1174, 1357, 1594, 3232, 3363. 
1H NMR (400 MHz, DMSO-d6) 2.61 (s, 3H,-CH3), 2.9 (dd, 1H,-CH2), 3.6 
(dd, 1H,-CH2),3.9 (s, 6H, 2-OCH3), 4.85 (td, 1H,-CH), 7.4 (m, 4H, ArH), 
7.6 (s, 2H,-NH2), 7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, ArH). 
[13]C NMR (100 MHz, DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 55.6, 57.4, 
62.2 (C-N), 108.2, 110.5, 120.2, 128.8, 128.9, 132.0, 132.3, 139.6, 142.3, 
143.8 (C-Ar), 145.2 (C-SO2), 151.9, 153.2 (ArC-OCH3). ESI-MS: m/z 443 
(M+1) observed for C20H22N6O4S, Anal calcd: C, 54.29; H, 5.01; N, 18.99; 
O, 14.46; S, 7.25; found: C, 53.01; H, 6.29; N, 17.46; O, 14.99; S, 8.25; 
4-(4-(5-(4-(Dimethylamino)phenyl)-4,5-dihydro-1H-pyrazol-3-
yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (4j): Yield 
62 %, mp 220-222 °C. IR spectrum, ν, cm-1: 1174, 1357, 1590, 3232, 
3373. 1H NMR (400 MHz, DMSO-d6) 2.61 (s, 3H,-CH3), 2.9 (s, 6H,-
N(CH3)2),3.05 (dd, 1H,-CH2), 3.6 (dd, 1H,-CH2), 4.9 (td, 1H,-CH), 7.4 (m, 
4H, ArH), 7.6 (s, 2H,-NH2), 7.7 (s, 1H,-NH), 7.9 (d, 2H, ArH), 8.1 (d, 2H, 
ArH). [13]C NMR (100 MHz, DMSO-d6) δ: 10.4(CH3), 25.2 (N(CH3)2), 
42.3 (C-Py), 62.2 (C-N), 125.9, 127.5, 128.8, 128.9, 132.0, 132.3, 139.6, 
141.2, 142.3, 143.8 (C-Ar), 145.2 (C-SO2),. ESI-MS: m/z 426 (M+1) 
observed for C20H23N7O2S, Anal calcd: C, 56.45; H, 5.45; N, 23.04; O, 
7.52; S, 7.54; found: C, 55.45; H, 6.45; N, 22.04; O, 8.54; S, 7.52; 
4-(5-Methyl-4-(5-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)-
1H-1,2,3-triazol-1-yl)benzenesulfonamide (4k): Yield 95 %, mp 
170-172 °C. IR spectrum, ν, cm-1: 1174, 1346, 1591, 3232, 3333. 1H 
NMR (400 MHz, DMSO-d6) 2.58 (s, 3H, CH3), 2.95 (dd, 1H,-CH2), 3.6 
(dd, 1H,-CH2), 4.85 (td, 1H, CH), 7.3 (d, 2H, ArH), 7.42-7.47 (m, 1H, 
ArH), 7.6 (s, 2H, NH2), 7.7 (s, 1H, NH), 7.9 (d, 2H, ArH), 8.14 (d, 2H, 
ArH). [13]C NMR (100 MHz, DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 
62.2 (C-N), 125.9, 127.5, 128.8, 128.8, 132.0, 132.3, 138.4, 139.6, 
142.3, 143.8 (C-Ar), 145.2 (C-SO2). ESI-MS: m/z 389 (M+1) observed 
for C16H16N6O2S2, Anal calcd: C, 49.47; H, 4.15; N, 21.63; O, 8.24; S, 
16.51; found: C, 48.15; H, 5.47; N, 20.63; O, 8.51; S, 17.24; 
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4-(4-(5-(Furan-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)-5-methyl-1H-
1,2,3-triazol-1-yl)benzenesulfonamide (4l): Yield 78 %, mp 190-
192 °C. IR spectrum, ν, cm-1: 1092, 1174, 1346, 1591, 3232, 3333. 1H 
NMR (400 MHz, DMSO-d6) 2.58 (s, 3H, CH3), 2.95 (dd, 1H,-CH2), 3.6 
(dd, 1H,-CH2), 4.85 (td, 1H, CH), 7.3 (d, 2H, ArH), 7.42-7.47 (m, 1H, 
ArH), 7.6 (s, 2H, NH2), 7.7 (s, 1H, NH), 7.9 (d, 2H, ArH), 8.14 (d, 2H, 
ArH). [13]C NMR (100 MHz, DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 62.2 
(C-N), 125.95, 127.59, 128.84, 128.84, 132.09, 132.35, 138.45, 139.64, 
142.34, 143.81 (C-Ar), 145.28 (C-SO2). ESI-MS: m/z 373 (M+1) 
observed for C16H16N6O3S, Anal calcd: C, 51.60; H, 4.33; N, 22.57; O, 
12.89; S, 8.61; found: C, 50.33; H, 5.60; N, 21.61; O, 13.89; S, 8.57; 
4-(4-(1,5-Diphenyl-4,5-dihydro-1H-pyrazol-3-yl)-5-methyl-1H-
1,2,3-triazol-1-yl)benzenesulfonamide (5a): Yield 75 %, mp 120-
122 °C. IR spectrum, ν, cm-1: 1163, 1336, 1593, 3192, 3223. 1H NMR 
(400 MHz, DMSO-d6): 2.7 (s, 3H, CH3), 3.2 (dd, 1H, CH2), 4.13 (dd, 1H, 
CH2), 5.5 (td, 1H, CH), 6.7 (m, 1H, ArH), 6.95 (d, 2H, ArH), 7.15-7.25 
(m, 5H, ArH), 7.26-7.7 (m, 8H, ArH, NH2). [13]C NMR (100 MHz, 
DMSO-d6) δ: 10.4 (CH3), 42.3 (C-Py), 63.2 (C-N), 123.1, 125.1, 125.9, 
127.5, 128.8, 128.9, 131.9, 132.0, 132.3, 137.9, 138.4, 139.6, 142.3, 
143.8 (Ar-C), 145.2 (C-SO2). ESI-MS: m/z 459 (M+1) observed for 
C24H22N6O2S, Anal calcd: C, 62.86; H, 4.84; N, 18.33; O, 6.98; S, 6.99; 
found: C, 61.84; H, 5.86; N, 17.98; O, 7.99; S, 6.33; 
4-(4-(5-(4-Chlorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-
5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5b): Yield 76 
%, mp 129-131 °C. IR spectrum, ν, cm-1: 756, 1163, 1338, 1596, 3213. 1H 
NMR (400 MHz, DMSO-d6): 2.7 (s, 3H, CH3), 3.2 (dd, 1H, CH2), 4.13 (dd, 
1H, CH2), 5.5 (td, 1H, CH), 6.7 (m, 1H, ArH), 6.95 (d, 2H, ArH), 7.15-7.25 
(m, 4H, ArH), 7.26-7.7 (m, 8H, ArH, NH2). [13]C NMR (100 MHz, DMSO-
d6): δ 10.4 (CH3), 42.3 (C-Py), 63.2 (C-N), 123.1, 125.1, 125.9, 127.5, 
128.9, 129.95, 131.95, 132.09, 132.35, 137.95, 139.5, 139.6, 142.3, 143.8 
(Ar-C), 145.2 (C-SO2). ESI-MS: m/z 493 (M+1) observed for 
C24H21ClN6O2S, Anal calcd: C, 58.47; H, 4.29; Cl, 7.19; N, 17.05; O, 6.50; S, 
6.50; found: C, 58.29; H, 4.50; Cl, 7.47; N, 16.05; O, 7.49; S, 6.20; 
4-(4-(5-(4-Fluorophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-
yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5c): 
Yield 75 %, mp 160-162 °C. IR spectrum, ν, cm-1: 832, 1163, 1332, 
1600, 3233. 1H NMR (400 MHz, DMSO-d6): 2.7 (s, 3H, CH3), 3.2 (dd, 
1H, CH2), 4.13 (dd, 1H, CH2), 5.5 (td, 1H, CH), 6.7 (m, 1H, ArH), 6.95 
(d, 2H, ArH), 7.15-7.25 (m, 4H, ArH), 7.26-7.7 (m, 8H, ArH, NH2). 
[13]C NMR (100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3(C-Py), 63.2 (C-
N), 119.5, 123.1, 125.1, 127.5, 128.8, 128.9, 131.9, 132.0, 132.3, 
137.9, 139.6, 142.3, 143.1 (Ar-C), 145.2 (C-SO2), 147.5 (C-F). ESI-MS: 
m/z 477 (M+1) observed for C24H21FN6O2S, Anal calcd: C, 60.49; H, 
4.44; F, 3.99; N, 17.64; O, 6.72; S, 6.72; found: C, 61.44; H, 3.49; F, 
4.64; N, 16.99; O, 6.73; S, 6.71; 
4-(4-(5-(4-Bromophenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-3-
yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5d): 
Yield 73 %, mp 132-134 °C. IR spectrum, ν, cm-1: 840, 1153, 1340, 
1600, 3233. 1H NMR (400 MHz, DMSO-d6): 2.7 (s, 3H, CH3), 3.2 (dd, 
1H, CH2), 4.13 (dd, 1H, CH2), 5.5 (td, 1H, CH), 6.7 (m, 1H, ArH), 6.95 
(d, 2H, ArH), 7.15-7.25 (m, 4H, ArH), 7.26-7.7 (m, 8H, ArH, NH2). 13C 
NMR (100 MHz, DMSO-d6): δ 10.4(CH3), 42.3 (C-Py), 63.2 (C-N), 
123.1, 124.4, 125.1, 126.9, 127.5, 128.8, 128.9, 131.9, 132.3, 137.9, 
138.4, 139.6, 142.3, 143.8 (Ar-C), 145.2 (C-SO2). ESI-MS: m/z 537 
(M+1) observed for C24H21BrN6O2S, Anal calcd: C, 53.64; H, 3.94; Br, 
14.87; N, 15.64; O, 5.95; S, 5.97; found: C, 53.94; H, 3.97; Br, 15.87; N, 
14.64; O, 5.94; S, 5.64; 
4-(5-Methyl-4-(5-(4-nitrophenyl)-1-phenyl-4,5-dihydro-1H-
pyrazol-3-yl)-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5e): 
Yield 80 %, mp 154-156 °C. IR spectrum, ν, cm-1: 1114, 1357, 1592, 
3192. 1H NMR (400 MHz, DMSO-d6): 2.59 (s, 3H, CH3), 2.9 (dd, 1H, 
CH2), 3.6 (dd, 1H, CH2), 4.85 (td, 1H, CH), 6.95-7.15 (m, 3H, ArH), 
7.18 (d, 2H, ArH), 7.4 (m, 4H, ArH), 7.6 (s, 2H, NH2), 7.7 (d, 2H, ArH), 
7.9 (d, 2H, ArH). [13]C NMR (100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3 
(C-Py), 63.2 (C-N), 123.1, 125, 125.9, 127.5, 128.8, 128.9, 131.9, 
132.0, 132.3, 137.9, 139.6, 142.3, 143.8 (Ar-C), 145.2 (C-SO2), 149.2 
(ArC-NO2). ESI-MS: m/z 504 (M+1) observed for C24H21N7O4S, Anal 
calcd: C, 57.25; H, 4.20; N, 19.47; O, 12.71; S, 6.37; found: C, 56.20; H, 
5.25; N, 20.71; O, 12.37; S, 5.47; 
4-(4-(5-(4-Methoxyphenyl)-1-phenyl-4,5-dihydro-1H-pyrazol-
3-yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5f): 
Yield 78 %, mp 125-127 °C. IR spectrum, ν, cm-1: 1106, 1343, 1600, 
3233. 1H NMR (400 MHz, DMSO-d6): 2.25 (s, 3H, CH3), 3.2 (dd, 1H, 
CH2), 3.78 (s, 3H, OCH3), 4.15 (dd, 1H, CH2), 5.5 (td, 1H, CH), 7.05 (m, 
1H, ArH), 7.2 (d, 2H, ArH), 7.3-7.6 (m, 9H, ArH, NH2), 7.85-8.14 (m, 
3H, ArH). [13]C NMR (100 MHz, DMSO-d6): δ 10.446 (CH3), 42.3 (C-
Py), 55.6 (OCH3), 63.2 (C-N), 123.1, 123.9, 125.1, 127.5, 128.8, 128.9, 
131.9, 132.0, 132.3, 137.9, 139.6, 142.3, 143.8 (Ar-C), 145.2 (C-SO2), 
151.9 (ArC-OCH3). ESI-MS: m/z 489 (M+1) observed for C25H24N6O3S, 
Anal calcd: C, 61.46; H, 4.95; N, 17.20; O, 9.82; S, 6.57; found: C, 
60.56; H, 4.20; N, 17.82; O, 9.95; S, 7.47; 
4-(4-(1-(4-Fluorophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-yl)-
5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5g): Yield 75 
%, mp 120-122 °C. IR spectrum, ν, cm-1: 1174, 1357, 1689, 3192, 3273. 
1H NMR (400 MHz, DMSO-d6): 2.65 (s, 3H, CH3), 3.15 (dd, 1H, CH2), 4.15 
(dd, 1H, CH2), 5.38 (td, 1H, CH), 6.9-7.17 (m, 4H, ArH), 7.5 (d, 2H, ArH), 
7.6 (s, 2H, NH2), 7.8-8.16 (m, 7H, ArH). [13]C NMR (100 MHz, DMSO-d6): 
δ 10.4 (CH3), 42.3 (C-Py), 63.2 (C-N), 119.5, 123.1, 125.1, 127.5, 128.8, 
128.9, 131.9, 132.0, 132.3, 137.9, 139.6, 142.3, 143.8 (Ar-C), 145.2 (C-
SO2), 147.5 (C-F). ESI-MS: m/z 477 (M+1) observed for C24H21FN6O2S, 
Anal calcd: C, 60.49; H, 4.44; F, 3.99; N, 17.64; O, 6.72; S, 6.72; found: C, 
61.44; H, 3.49; F, 4.64; N, 16.99; O, 6.73; S, 6.71; 
4-(4-(1-(4-Bromophenyl)-5-phenyl-4,5-dihydro-1H-pyrazol-3-
yl)-5-methyl-1H-1,2,3-triazol-1-yl)benzenesulfonamide (5h): 
Yield 77 %, mp 135-137 °C. IR spectrum, ν, cm-1: 856, 1163, 1338, 
1596, 3213. 1H NMR (400 MHz, DMSO-d6): 2.65 (s, 3H, CH3), 3.15 
(dd, 1H, CH2), 4.15 (dd, 1H, CH2), 5.38 (td, 1H, CH), 6.9-7.17 (m, 4H, 
ArH), 7.5 (d, 2H, ArH), 7.6 (s, 2H, NH2), 7.8-8.16 (m, 7H, ArH). [13]C 
NMR (100 MHz, DMSO-d6): δ 10.4 (CH3), 42.3 (C-Py), 63.2 (C-N), 
123.1, 124.4, 125.1, 126.9, 127.5, 128.8, 128.9, 131.9, 132.3, 137.9, 
138.4, 139.6, 142.3, 143.8 (Ar-C), 145.2 (C-SO2). ESI-MS: m/z 537 
(M+1) observed for C24H21BrN6O2S, Anal calcd: C, 53.64; H, 3.94; Br, 
14.87; N, 15.64; O, 5.95; S, 5.97; found: C, 53.94; H, 3.97; Br, 15.87; N, 
14.64; O, 5.94; S, 5.64; 
 
Table 1: Calculated docking scores, binding energies, H-bond count of the targeted compounds inside the PI3Kα active site 
Compound Libdock score H-Bond count 
3j 128.405 3 
3i 145.031 4 
3a 130.302 3 
3e 129.849 2 
3b 129.803 4 
5b 128.22 1 
4b 113.056 1 
3d 143.264 1 
4d 120.09 5 
3l 125.889 3 
4l 113.992 3 
3f 132.497 3 
5f 130.953 1 
4f 143.264 2 
3k 124.359 3 
5i 132.217 0 
4k 122.165 4 
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Yield 73 %, mp 100-102 °C. IR spectrum, ν, cm-1: 1161, 1334, 1595, 
3292. 1H NMR (400 MHz, DMSO-d6): 2.59 (s, 3H, CH3), 2.9 (dd, 1H, 
CH2), 3.6 (dd, 1H, CH2), 4.85 (td, 1H, CH), 6.96-7.14 (m, 3H, ArH), 
7.18 (d, 2H, ArH), 7.38 (d, 2H, ArH), 7.5 (d, 2H, ArH), 7.55-7.8 (m, 5H, 
ArH, NH2). [13]C NMR (100 MHz, DMSO-d6): δ 10.446 (CH3), 42.36 
(C-Py), 62.29 (C-N), 123.11, 125.11, 125.95, 127.59, 128.84, 128.84, 
131.95, 132.09, 132.35, 137.95, 138.45, 139.64, 142.34, 143.81 (Ar-
C), 145.28 (C-SO2). ESI-MS: m/z 465 (M+1) observed for 
C22H20N6O2S2, Anal calcd: C, 56.88; H, 4.34; N, 18.09; O, 6.89; S, 13.80; 
found: C, 56.34; H, 4.09; N, 18.89; O, 6.80; S, 13.88; 
Results of docking and ADMET 
Table 1 depicts the Libdock scores of top-ranked complex pose per 
compound along with their binding energies and number of 
hydrogen bonds. The molecular docking results of synthesized 
compounds revealed that among all the docked compounds, 
compound 3i possessed the high Libdock score of 145.031 
compared with the reference ligand KKR exhibiting a Libdock score 
of 88.35. Docking confirmation of reference ligand KKR with the 
active site of protein was shown in fig 2. From the table 1, it is 
revealed that all the compounds displayed convincing dock scores 
ranging from 145.031 to 122.165, which implies that the designed 
molecules possess a related mode of binding and valid binding 
affinity against the protein just as the reference ligand. The 
compound 3i is well fitted into the binding site of PI3Kα by 
hydrogen bonds and other close interactions. The interaction of the 
protein PI3Kα and compound 3i is shown in fig 3. From results it 
was observed that four hydrogen bond interactions were presented 
in the docked pose with compound 3i, two bonds with VAL851 and a 
single bond with each of the residues GLN859, LYS802. N10 and N11 
of the compound 3i interact with H-atom of the amine group of 
VAL851 forming two hydrogen bonds (A: VAL851: HN-3i: N10 and 
A: VAL851: HN-3i: N11) with a hydrogen bond distance of 1.941 Å 
and 2.359 Å respectively. Third hydrogen bond was formed when 
the hydrogen atom of GLN859 interacted with the oxygen atom of 
the compound 3i (A: GLN859:HE22-3i: O23) with a hydrogen bond 
distance of 1.882 Å. Another hydrogen bond was formed between 
the hydrogen atom of LYS802 and the oxygen atom of the compound 
3i (A: LYS802:HZ3-3i: O) with a hydrogen bond distance of 2.449 Å. 
A few non-bonded interactions were found between the compound 
3i and the residues TYR836, SER854, GLU849, VAL850, ILE932, 
ILE848, ASP810, ILE800, MET772, ASP933, MET858, and CYS862. 
 
 
Fig. 2: The docking conformation of reference drug KKR inside 
the protein PI3Kα binding site 
 
The ADMET screening results obtained for synthesized compounds 
are summarized in table 2 and compared with standard levels. As 
per discovery studio (DS) parameters, standard comparable values 
of human intestinal absorption as level 0, solubility as level 3 and 4, 
blood-brain barrier (BBB) penetration as level 3, non-inhibitory 
property with cytochrome-P(CYP450 2D6) as level 0, and non-
toxicity as level 0. An ADMET plot was generated for the blood-brain 
barrier penetration and the intestinal absorption using descriptors 
AlogP98 and 2D polar surphase area (PSA) that comprise confidence 
ellipses of 95% and 99%. These ellipses elucidate zones where well-
occupied compounds are expected to be settled. The compounds are 
found to be in the range of 95 and 99 % confidence ellipse for both 
the intestinal absorption and BBB as shown in fig. 4. 
 
 
Fig. 3: The hydrogen bond interactions of the compound 3i with 
the protein PI3Kα 
 
From the analyzed results, all the synthesized compounds showed a 
BBB level of 4 except for 4k which is 3. The BBB level 4 showing 
undefined penetration and level 3 indicating a little penetration 
across the central nervous system (CNS) hence it reduces the side 
effects linked to CNS. The absorption level was found to be 0 and 1 
for all the compounds revealing good and moderate intestinal 
absorption. For all the compounds, the calculated hepatotoxic level 
was 1 implying the compounds as toxic. The solubility level 3 
indicates very good solubility, level 2 indicates low solubility and 
level 1 indicates very low solubility or no solubility. All the 
compounds are found to be having the solubility level 2 except 3l, 
which was 3, compound 5b was 1. Similarly, compounds having level 
0 were found to be satisfactory with respect to CYP 450 2D6 liver 
enzyme, suggesting that the compounds are non-inhibitors of the 
metabolic enzyme and those having level 1 suggests that all the 
compounds are inhibitors of the metabolic enzyme. Finally, the PPB 
value found to be 2 for most of the compounds indicates that the 
compounds have binding ≥ 90 % and the compounds 3i, 4l and 5k 
are found to have 0 which denotes that the compounds have 
binding ≤90 % clearly reveal that the compounds have good 
bioavailability and are not likely to be highly bound to carrier 
proteins in the blood. 
 
 
Fig. 4: Plot of PSA versus LogP for candidate compounds 
showing the 95 and 99% confidence limit ellipses 
corresponding to the blood–brain barrier and intestinal 
absorption models
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AlogP98 2D PSA 
3j 4 0 2 1 0 2 2.757 109.665 
3i 4 1 2 1 0 0 2.562 124.172 
3a 4 0 2 1 0 2 2.594 106.312 
3e 4 0 2 1 0 2 3.343 106.312 
3b 4 0 2 1 0 2 3.259 106.312 
5b 4 1 1 1 1 2 4.612 103.687 
4b 4 0 2 1 0 2 2.83 113.145 
3d 4 1 2 1 0 2 3.179 121.367 
5c 4 0 2 1 0 2 2.371 113.145 
3l 4 0 3 1 0 2 1.99 118.866 
4l 4 0 2 1 0 0 1.454 125.699 
3f 4 0 2 1 0 2 2.578 115.242 
5f 4 1 2 1 1 2 3.932 112.617 
4f 4 1 2 1 0 2 3.179 121.367 
4k 3 0 2 1 0 2 2.32 106.312 
5i 4 0 2 1 1 2 3.567 103.687 
4k 4 0 2 1 0 0 1.785 113.145 
 
Cytotoxic activity 
Cytotoxic activity results were summarized in table 3. All tested 
compounds have shown significant cytotoxic activity.  
Among all the tested compounds, 3b and 4d exhibited significant 
percentage inhibition in cell proliferation at an IC50 value of 
4.54µg/ml and 7.75µg/ml as shown in fig. 5. 
 
Table 3: Cytotoxicity of synthesized compounds on MCF-7 cell line 
S. No. Compound IC50 value (µg/ml) 
1 3b 22.5 
2 3f 15.5 
3 3i 4.54 
4 3k 34.3 
5 3l 25.8 
6 4d 7.75 
7 4f 26 
8 4k 19.25 
9 4l 55.8 
10 5b 43.4 
11 Taxol (standard) 15 nmol 
 
 
Fig. 5: Graphical representation of IC50 values of compounds 3i and 4d 
 
Table 4: Effect of compound 4d on total leukocyte count (103/µl) in potassium oxonate induced gout in mice 
Groups  On 7thday On 14thday On 29thday 
Normal Control 7.862±0.729 7.862±0.729 7.862±0.729 
Disease Control 125.0±5.510 110.0±3.443 120.9±7.868 
Standard Control 101.7±4.728 77.80±5.001 24.69±0.786 
4d (50 mg/kg) 129.5±3.521 97.02±5.100 62.37±5.006 
4d(100 mg/kg) 107.1±5.094 66.46±2.954 13.59±1.762 
All the data are expressed as mean±SEM (n=6). 
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Table 4.1: Effect of compound 4d on neutrophils count (103/µl) in potassium oxonate induced gout in mice 
Groups On 7th day On 14th day On 29th day 
Normal Control 2.228±0.3582 2.228±0.3582 2.228±0.3582 
Disease Control 54.98±2.284 26.73±2.672 10.50±0.9429 
Standard Control 49.12±3.132 29.48±2.917 3.237±0.3677 
4d (50 mg/kg) 58.76±1.151 38.07±4.850 16.35±2.999 
4d (100 mg/kg) 48.07±4.850 22.16±1.875 6.305±1.037 
All the data are expressed as mean±SEM (n=6). 
 
Table 4.2: Effect of compound 4d on monocyte count (103/µl) in potassium oxonate induced gout in mice 
Groups   On 7thday On 14thday On 29thday 
Normal Control 0.18±0.043 0.18±0.043 0.18±0.043 
Disease Control 48.57±4.362 68.06±4.847 97.88±6.664 
Standard Control 36.72±2.663 34.19±2.433 19.07±1.032 
4d (50 mg/kg) 49.16±3.324 38.73±2.883 29.36±2.665 
4d (100 mg/kg) 38.73±2.883 33.69±3.270 3.457±0.418 
All the data are expressed as mean±SEM (n=6). 
 
Table 4.3: Effect of compound 4d on lymphocyte count (103/µl) in potassium oxonate induced gout in mice 
Groups   On 7thday On 14thday On 29thday 
Normal Control 5.47±0.554 5.47±0.554 5.47±0.554 
Disease Control 20.93±3.005 14.74±1.792 11.93±1.313 
Standard Control 15.64±1.958 13.91±1.444 2.338±0.406 
4d (50 mg/kg) 21.06±1.286 19.98±2.146 16.35±3.332 
4d (100 mg/kg) 19.98±2.146 10.38±0.733 4.910±0.5303 
All the data are expressed as mean±SEM (n=6). 
 
Table 4.4: Effect of compound 4d on eosinophil count (103/µl) in potassium oxonate induced gout in mice 
Groups   On 7thday On 14thday On 29thday 
Normal Control 0.03±0.006 0.03±0.006 0.03±0.006 
Disease Control 0.47±0.058 0.47±0.067 0.55±0.085 
Standard Control 0.22±0.034 0.21±0.036 0.040±0.013 
4d (50 mg/kg) 0.49±0.043 0.19±0.040 0.31±0.085 
4d 100 mg/kg) 0.29±0.040 0.21±0.030 0.24±0.078 
All the data are expressed as mean±SEM (n=6) 
 
Table 4.5: Effect of compound 4d on basophil count (103/µl) in potassium oxonate induced gout in mice 
Groups   On 7thday On 14thday On 29thday 
Normal Control 0.001±0.0004 0.001±0.0004 0.001±0.0004 
Disease Control 0.024±0.006 0.023±0.008 0.035±0.008 
Standard Control 0.029±0.006 0.023±0.006 0.003±0.0009 
4d (50 mg/kg) 0.028±0.004 0.037±0.011 0.023±0.009 
4d (100 mg/kg) 0.020±0.003 0.018±0.002 0.005±0.003 
All the data are expressed as mean±SEM (n=6). 
 
Table 5: Effect of compound 4d on erythrocyte sedimentation rate (mm/hr) in potassium oxonate induced gout in mice 




1 1.0 8.5 2.0 3.2 2.0 
2 2.0 5.9 4.6 4.9 4.0 
3 0.5 9.3 2.4 6.5 1.5 
4 2.0 10.0 3.7 7.3 2.4 
5 1.5 8.4 4.2 6.8 1.8 
6 1.0 11.0 1.1 5.5 0.9 
mean±SEM 1.333±0.2472 8.850±0.7112 3.000±0.5615 5.700±0.6148 2.100±0.4320 
All the data are expressed as mean±SEM (n=6). 
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Table 6: Effect of compound 4d on xanthine oxidase (U/ml) in potassium oxonate induced gout in mice 




1 1.69 4.94 1.94 1.67 1.57 
2 0.59 2.29 1.40 3.36 1.62 
3 1.59 3.01 2.23 2.36 1.91 
4 1.22 2.16 0.78 2.04 1.37 
5 1.64 2.31 1.67 3.05 1.45 
6 0.54 4.35 1.52 4.10 2.33 
mean±SEM 1.212±0.2155 3.177±0.4860 1.590±0.2029 2.763±0.3700 1.708±0.1455 
All the data are expressed as mean±SEM (n=6). 
 
Table 7: Effect of compound 4d on serum creatinine levels (mg/dl) in potassium oxonate induced gout in mice 




1 2.5 4.69 3.21 4.03 1.44 
2 2.0 3.38 2.94 2.89 0.96 
3 1.5 3.23 1.06 5.23 3.50 
4 2.5 2.61 1.72 3.12 1.70 
5 1.0 5.30 1.39 4.27 2.40 
6 1.0 6.01 2.58 1.98 1.30 
mean±SEM 1.750±0.2814 4.203±0.5437 2.150±0.3598 3.587±0.4708 1.883±0.3787 
All the data are expressed as mean±SEM (n=6). 
 
Table 8: Effect of compound 4d on serum uric acid (mg/dl) in potassium oxonate induced gout in mice 




1 2.74 9.65 5.50 6.69 2.68 
2 2.82 11.17 5.57 6.38 2.94 
3 2.1 11.01 5.37 6 3.62 
4 2.54 13.05 5.43 6.56 2.99 
5 2.34 11.44 6.43 6.86 3.07 
6 1.91 11.95 6.06 6.21 3.44 
mean±SEM 2.408±0.1466 11.38±0.4579 5.727±0.1729 6.450±0.1295 3.123±0.1412 
All the data are expressed as mean±SEM (n=6). 
 
Table 9: Effect of compound 4d on blood urea nitrogen (mg/dL) in potassium oxonate induced gout in mice 
Animal no Normal control Disease control Standard control Compound 4d (50 mg/kg) Compound 4d (100 mg/kg) 
1 16.93 32.72 23.24 27.12 13.25 
2 17.26 60.70 30.74 31.58 18.38 
3 17.08 58.59 28.05 35.83 15.22 
4 16.8 47.97 33.28 33.05 17.92 
5 16.3 53.88 25.93 42.67 22.67 
6 15.01 46.95 25.04 38.87 21.84 
mean±SEM 16.56±0.3379 50.14±4.144 27.71±1.534 34.85±2.251 18.21±1.491 
All the data are expressed as mean±SEM (n=6). Data analysed by one way ANOVA followed by tukeys test. αP<0.05, when compared to normal 
control. βP<0.05 when compared to disease control. γP<0.05 when compared to low dose. 
 
CONCLUSION 
In this study, we have designed and synthesized a novel series of 
pyrazoline incorporated 1, 2, 3-triazole benzene sulphonamides and 
performed docking simulations in order to identify their binding affinity 
towards the selected target protein PI3Kα and tested for their ADMET 
profiles. Among all the compounds, compound 3i displayed preferred 
binding orientations along with strong affinities towards the active site 
of PI3Kα with better ADMET profile. The synthesized compounds were 
examined for cytotoxic activity and compound 3i exhibited higher 
activity with an IC50 value of 4.54 µg/ml. In Anti-inflammatory activity 
compound, 4d has significantly shown an anti-inflammatory effect on 
potassium oxonate induced gout and this was mediated by suppressing 
the inflammatory responses.  
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